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Cancer is one of the most devastating diseases affecting the life of
many people around the world. Despite advances in surgical and radia-
tion treatments, chemotherapy continues to be an important therapeu-
tic option for different malignancies, especially for primary advanced
and metastatic tumors. However, the efﬁcacy of chemotherapy is
substantially limited by the intrinsic and acquired resistance of cancer
cells to anticancer drugs [1]. Although several approaches have been re-
cently developed and tested for the suppression of such resistance
[2–5], their efﬁcacy ﬂuctuates signiﬁcantly in different patients due to
the wide variations of drug resistance mechanisms among individual
patients. Among patients placed in identical chemotherapeutic proto-
cols, some of themmay receive relatively ineffective doses of anticancer
agents while other individuals obtain excessive amounts of drugs that
induce severe adverse side effects on healthy tissues. Hence, the individ-
ualized selection of drug doses and targets to suppress resistance
based on the molecular characteristics of tumors can potentially im-
prove the treatment outcome and bring us closer to an era of personal-
ized medicine.
The aim of the present review is to describe major mechanisms of
drug resistance and approaches to overcomeor suppress themwith em-
phasis on personalized selection of drugs and methods of treatment
based on the individual genetic proﬁle of patient tumors. Here, we pro-
pose a novel approach to the personalized selection of effective treat-
ment for each individual cancer patient based on the genotype and
phenotype proﬁles of the tumor samples obtained from the same pa-
tient. We try to establish a correlation between genetic data observed
in tumor tissues obtained from patients, their individual resistance to
different drugs, and the efﬁciency of the treatment. It is expected that
such a correlation will be established and used for the selection of the
most effective treatment for an individual patient. It is expected that
the proposed approach will enhance the effectiveness of treatment of
primary tumors, prevent the development of metastases, and limit se-
vere adverse side effects on healthy tissues and organs.2. Mechanisms of multidrug resistance
During the initial phase of chemotherapy, an anticancer drug kills
most of the cancer cells. However, not all of the cells are killed. Some
cells survive the treatment and initiate further regrowth of cancer
cells. Inmany cases new cancer cells become resistant to the treatment.
To overcome the resistance to the previously used drug, a treatment
with another drug or combination of several drugswith differentmech-
anisms of action is used [6–9]. However, in the late phase of chemother-
apy, cancer cells become resistant not only to the drugs that were
previously used for the treatment but to many anticancer drugs with
distinct mechanisms of cancer killing. Such type of cellular resistancewhen tumor cells treated with one anticancer drug become resistant
to a whole spectrum of drugs is usually termed as multidrug resistance
[5]. Multidrug resistance can be intrinsic or acquired. Important subsets
of cancer cells that are notorious for intrinsic drug resistance are called
cancer initiating or stem cells [10–14]. These cells overexpress certain
stem cell markers, survive treatment with anticancer drug(s), and initi-
ate a growth of new tumor cells that in most cases possess multidrug
resistance.
The development of multidrug resistance in cancer cells as other
types of adaptation to any stress includes short-term (initial or urgent)
and long-term stages. Short-term phase of adaptation arises directly
after the irritant starts to act, occurs on the basis of ready, performed bi-
ological mechanisms and is incomplete. During this stage the organism
functions at the limit of its physiological potential. This initial stage of ad-
aptation usually leads to the more or less pronounced damage of the
cells. In contrast, long-term adaptation arises gradually as a result of re-
peated or long-term environmental action (in case of chemotherapy—
prolonged or repeated action of anticancer drug(s)). This type of adapta-
tion of cancer cells to chemotherapy develops on the basis of repeated
realization of urgent adaptation. As a result, a cancer cell acquires a
new quality: from a drug sensitive cell, a drug resistant cell evolves.
The mechanisms used by the cell to avoid death by the speciﬁc drug, in
many instances render the cell resistant to yet additional drugs that the
cell has never being in contact with. Mechanisms of intrinsic and ac-
quired resistance are similar and include two major types of resistance
that we termed as “pump” and “nonpump” resistance [15–18] (Fig. 1).2.1. Pump resistance
Pump resistance depends on membrane-bound active drug efﬂux
pumps that expel anticancer drugs from the cytoplasm out from the
cells. Today, many such drug efﬂux transporters have been identiﬁed
[19–22] (Fig. 1). The main drug efﬂux transporters include but are not
limited to P-Glycoprotein (encoded in human by the MDR1 gene), a
family of multidrug resistance-associated proteins (MRP), lung resis-
tance proteins (LRP), breast cancer resistance proteins (BCRP), and
many others. Active drug efﬂux systems can be divided into two fami-
lies. The ﬁrst family of drug efﬂux pumps consists of a single transmem-
brane protein that efﬂuxes drugs by using proton-motive forces. The
second family includes the adenosine triphosphate (ATP)-binding cas-
sette (ABC) transporters. The later mechanism is very important in the
development of multidrug resistance of cancer. A typical structure of
the ABC transporters includes four or ﬁve membrane-associated do-
mains (Fig. 2) [23,24]. Two or three domains are highly hydrophobic
and each consists of ﬁve or six putative transmembrane segments in
α-helical conﬁguration. These transmembrane domains (TMD1 and
TMD2 in Fig. 2) form the pathway for drug efﬂux. The other two do-
mains are nucleotide-binding domains (NBD1 and NBD2 in Fig. 2),
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lowing mechanism plays a major role in the drug efﬂux by ABC pumps
(Fig. 3) [24]. An anticancer drug enters the membrane by diffusion and
interacts with drug-binding domains (DBD) of the transporter (formed
by the transmembrane domains 6, 5, 11, and 12 in P-glycoprotein). Such
binding stimulates ATP hydrolysis at nucleotide-binding domains
(NBD) of the protein. This hydrolysis changes a conﬁguration of NBDs
that reduces the afﬁnity of the drug and leads to the drug efﬂux. It
should be stressed that the drug ought to have a relatively lowmolecu-
lar weight and should be internalized by cancer cells via “simple” phys-
ical diffusion in order to be pumped out from the cells by such drug
efﬂux pumps. This is a very important requirement that allows for over-
coming pump resistance of cancer cells. For example, changing the
mechanism of drug internalization from diffusion to endocytosis and
receptor-mediated endocytosis would bypass the pump.
2.2. Nonpump resistance
Several mechanisms of drug resistance in cancer cells are indepen-
dent from drug efﬂux pumps [25]. We proposed the term “nonpump”
resistance to classify such mechanisms [15–18]. Although, mechanisms
responsible for cellular nonpump resistance can be substantially differ-
ent, they, however, all are independent from the drug efﬂux pumps
(Fig. 1). Unlike the drug efﬂux pumps, nonpump resistancemechanismsNBD1NH2
Extracellular
Intracellular
Membrane
TMD1
Fig. 2. Predicted secondary structure of the P-glycoprotein. The pump consists of four domain
nucleotide-binding domains (NBD) are located at the cytoplasmic surface of the membrane a
segments—helices. Modiﬁed from [24].do not interferewith the entry and accumulation of drugs in tumor cells.
Instead, they decrease the ability of an anticancer drug to induce cell
death or prevent drug-induced damage frombeing efﬁciently translated
into cell death. A cancer cell possesses many processes that prevent cell
death from an anticancer drug, including but not limited to the follow-
ing classes: drug inactivation and degradation, antiapoptotic and anti-
oxidant defenses, DNA repair, replication, and biosynthesis.
Antiapoptotic defense represents one of the major mechanisms of
cellular nonpump drug resistance in cancer cells. This system is de-
signed to prevent transformation of a damage induced by an anticancer
drug into apoptotic cell death. A huge complex of proteins is involved in
cellular antiapoptotic defense. However, the BCL2 protein is a major
player in this process in most cancer cells. It is generally believed that
BCL2 prevents the release on cytochrome c from mitochondria and
therefore breaks apoptotic signal ﬁnally preventing the activation of
caspases and apoptosis itself [26]. We found that suppression of this
protein effectively prevents apoptosis in several types of cancer cells
after treatment with anticancer drug(s) and substantially increased cy-
totoxicity of the drugs [17,27–33]. Consequently, BCL2 and other
antiapoptotic members of the BCL2 family represent attractive targets
for the suppression of nonpump resistance.
Cancer cells have several mechanisms of enzymatic inactivation or
degradation of anticancer drugs. Both in vitro and in vivo experiments
showed that the activation in cancer cells of certain drug detoxiﬁcationCarbohydrates
NBD2 COOH
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Fig. 3. Proposed working model of P-glyciprotein-mediated drug efﬂux. The residues of the transmembrane domain form the drug-binding domain (DBD). The substrate enters the lipid
bilayer and interacts with the drug-binding domain. The binding of the substrate stimulates ATP hydrolysis. Hydrolysis of ATP at nucleotide-binding domains (NBD) leads to a conforma-
tional change in NBD that reduces the afﬁnity for the substrate and leads to drug efﬂux. Modiﬁed from [24].
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overexpressed in the liver) in response to an anticancer drug exposure
[34–36], leads to a decrease in cytotoxicity and, consequently reduces
the ability of the drug to induce cell death.
Many anticancer drugs induce free radicals or activate peroxidation
processes inside cancer cells [35–43]. Themajor consequence of activat-
ed free radical process inside the cells results in the activation of lipid
peroxidation—a free radical chain reaction [44–46]. Similar oxidative
damage can occur on the level of proteins and nucleic acids [47,48]. A
hydroxyl radical attacks polyunsaturated fatty acids in biological mem-
branes forming the lipid radicals which further induce the creation of
lipid peroxy radicals in thepresence of oxygen. These radicals altogether
may interact with a new molecule of fatty acid producing lipid hydro-
peroxide and the next lipid radical initiating a chain reaction that dam-
age cellular membranes. A powerful antioxidant system is developed in
cancerous and normal cells in order to protect cells fromoxygen radicals
continuously generating in the cells during their normal life cycle
[46,48,49]. Antioxidant defense strategies include prevention, intercep-
tion, replacement, and repair [50,51]. The major antioxidant systems
include the cytochromes, superoxide dismutase, catalase, glutathione
peroxidase, and antioxidants (a-tocopherol, steroids, thyroxine, etc.).
This entire antioxidant system also plays an important role in protecting
cancer cells against free radicals initiated by the drug exposure.
DNA repair, replication and biosynthesis are the next important
mechanisms of nonpump resistance of cancer cells against the exposure
to an anticancer drug. Certain anticancer drugs can induce DNA damage
directly or indirectly. Such damage, if not repaired, can lead to cell
death. Normal cells have a robust and well-developed system that pre-
vents and repairs DNA damage. The same mechanisms are being used
by cancer cells to limit DNA damage induced by an anticancer drug
during chemotherapy. For instance, a widely used anticancer drug
doxorubicin damages the cells by intercalatingDNA and inhibitingmac-
romolecular biosynthesis. Doxorubicin stabilizes the topoisomerase II
complex preventing the release of DNA double helix and stopping the
process of replication [52,53]. However, resistant cancer cells can acti-
vate topoisomerases in response to doxorubicin treatment in order to
compensate the damaged molecules and thereby increase the resis-
tance against the treatment.
Several othermechanisms that do not involve drug efﬂux pumps are
activated in drug resistant cancer cells ﬁnally leading to nonpump resis-
tance to chemotherapy. These mechanisms may include an entire sys-
tem of stress proteins (including heat shock proteins), activation of
cellular metabolism, interception of cell death signal, etc. However, it
should be stressed that all these mechanisms of nonpump resistancedepend on the overexpression of certain proteins. Some of these pro-
teins are constitutive (are found in the cell under normal conditions),
while others have been found to be induced in response to a variety of
cellular stresses including chemotherapy. Such an overexpression can
be detected in the samples of tumor tissues isolated from a patient.
Corresponding inhibitors of these proteins (such as siRNA or antisense
oligonucleotides) could be selected and further used for personalized
treatment.
3. Overcoming multidrug resistance
3.1. Increasing drug concentration
3.1.1. Systemic drug delivery
Drug resistant cells survive the applied concentration(s) of anticancer
drug(s). The simplest way to overcome drug resistance of cancer cells is
an increase in the concentration of the drugs or use of multiple drugs
with differentmechanisms of action. However, high doses of chemother-
apeutic agents delivered by oral or parenteral routes are extremely dan-
gerous. When a drug is not targeted speciﬁcally to cancer cells, it can
potentially induce severe adverse side effects upon healthy tissues and
cells even if some protective actions are taken. Consequently, this ap-
proach cannot be considered as a valuable tool to overcomemultidrug re-
sistance. In order to overcome these delinquencies of the systemic
delivery of high doses of anticancer drugs, some approaches were devel-
oped. These approaches are aimed at delivering higher drug concentra-
tions in order to overcome multidrug resistance of cancer cells include
local (topical) drug delivery and targeting of anticancer drugs to tumors.
3.1.2. Local (topical) drug delivery
Local drug delivery has a distinct advantage over the systemic deliv-
ery. When a drug is delivered directly to the site of action, its local con-
centration in targeted cells increases while the adverse side effects
generally are limited. However, the delivery of the drug locally to tu-
mors represents substantial difﬁculties unless the tumor is readily
accessed from the outside. Unless the cancer is located on the skin or
accessible organs, achievement of this task is difﬁcult. One prospective
organ suitable for a local delivery of anticancer therapeutics is the
lung. For a long time the lungs were used for a systemic and local
delivery of therapeutics. One of the oldest examples of respiratory ad-
ministration for systemic drug delivery is inhalation anesthesia. An in-
creasing variety of drugs are being administered by this route to
obtain a direct effect on the target tissues of the respiratory system, in-
cluding beta-agonists, corticosteroids, mast cell stabilizers, antibiotics,
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tration is being used increasingly for other medications, such as vasoac-
tive drugs for resuscitation, sedatives, antioxidants and hormones
[57,65–71]. However, using of inhalations or intratracheal injection of an-
ticancer drugs in order to treat lung cancer is currently only exploratory.
Recently, we investigated the efﬁcacy of the delivery of drugs by in-
halation when compared to the intravenous route of administration in
order to treat lung cancer [29,32,72,73]. Nanostructured lipid carriers
(NLC) and liposomeswere used asmodel carriers to deliver drugs local-
ly into the lungs by inhalation. It should be stressed that most types of
anticancer drugs and nucleic acids can be effectively delivered by inha-
lation using these types of nanocarriers. It was found that 40% to 60% of
both NLC and liposomes were accumulated in the liver and only less
than 25% of the injected dose were found in the lungs after intravenous
injection (Fig. 4A) [32,69]. In contrast, the same carriers delivered by in-
halation accumulated predominately in the lungs. In fact, around 80% of
the carrierswere found in the lungs after inhalation (Fig. 4A). These data
support the efﬁciency of such types of local delivery of therapeutics in
the treatment of lung diseases including lung cancer.
Another approach to the local delivery of anticancer agents includes
the conjugation of anticancer drugs to some carriers that can be guided
to the tumor site. This guidance can be achieved for instance by an ex-
ternal magnetic ﬁeld if the drugs or other therapeutic agents are conju-
gated to magnetic nanoparticles [74]. However, such delivery options
possess some limitations and can induce adverse side effects.
In summary, in order to overcome drug resistance, high doses of an-
ticancer drugs can be delivered locally to skin, lungs, or other accessible
organs. However, for the most organs and tissues this approach is not
feasible.
3.1.3. Passive targeting
Some anticancer drugs can be modiﬁed in order to ensure their pref-
erential accumulation in targeted tumors.We proposed to subdivide dif-
ferent approaches to targeting of anticancer and other drugs speciﬁcallyto the site of action into two big clusters: passive and active targeting
[34]. Active targeting is usually achieved when the drug is conjugated
to a carrier togetherwith a targeting component that redirects the carrier
and associated drug to the speciﬁc cells. Passive targeting includes mod-
iﬁcations of drug or drug formulations other than using targeting moie-
ties in the way that provides for a preferential accumulation of the
modiﬁed drug speciﬁcally in the tumor or tumor environment.
The oldest and most known approach for a passive targeting of anti-
cancer drugs to tumors is the use of enhancedpermeability and retention
effect (EPR). The EPR effectwas ﬁrst described byMaeda and co-workers
[75,76]. The EPR effect is the result of the increased permeability of the
tumor vascular endothelium to circulating macromolecules combined
with limited lymphatic drainage from the tumor interstitium. High mo-
lecularweight substances or lowmolecular drugs coupledwith highmo-
lecular weight carriers penetrate highly vascularized tumor tissues, are
inefﬁciently removed by lymphatic drainage and therefore accumulate
in tumors. The existence of the EPR effect was experimentally conﬁrmed
for many types of macromolecular anticancer drug delivery systems
[77–79]. Despite the simplicity of the approach it has serious disadvan-
tages. The accumulation of high molecular weight substances occurs
only to solid tumors with developed vascularization, high tumor mass
and poor lymphatic drainage. However, these types of solid tumors can
be relatively easy removed by surgery. The efﬁciency of this type of
passive targeting is low for multifocal metastatic tumors that cannot be
removed using surgical procedures and requires chemotherapy. Conse-
quently, the EPR effect cannot be effectively used for overcoming drug
resistance in most tumors that badly require it.
Several other approaches have been proposed for a passive targeting
of anticancer drugs speciﬁcally to tumor cells. Most of them use speciﬁc
tumor conditions to release anticancer drugs from the delivery system
speciﬁcally to the tumor environment or in tumor cells [34]. These con-
ditions include but are not limited to particular pH, existence of certain
enzymes or microﬂora in speciﬁc organ or tumor. Two main disadvan-
tages limit the applicability of such approaches to overcome multidrug
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targeting are based on the conditions (e.g.microﬂora in gastrointestinal
tract) that are attributed to the entire affected organ not tumor itself
[34,80–88]. This passive targeting option does not protect healthy cells
and tissues from the targeted organ against the destructive action of
highly toxic anticancer agents. Second, targeted tumor conditions (such
as pH, or expression of certain enzymes) can often be found (although
usually in less pronounced degree) in healthy organs and cells. The latter
opens a door for severe adverse side effects of chemotherapy.
3.2. Overcoming drug resistance
As previouslymentioned, the drug efﬂuxpumps inﬂuence smallmo-
lecular weight substances that cross the plasma membrane of cancer
cells by s “simple” diffusion. Consequently, if the mechanism of the in-
ternalization of a drug could be changed from diffusion to other type
of internalization, theoretically the drug would avoid efﬂux pumps
and therefore overcome pump resistance. Endocytosis is a mechanism
of drug entry into cancer cells that can be successfully used to overcome
drug efﬂux pumps.
3.2.1. Endocytosis versus diffusion
Diffusion in its application to cellular internalization of drugs is a
“passive” process of mass transfer of drug molecules caused by random
molecular motion and associated with a concentration gradient of a
substance on two sides of the plasma membrane. If the concentration
of molecules of a drug outside the cell is higher than inside, more mol-
ecules of a drug will move per unit of time inside the cell than in the
opposite direction and therefore the drug will be accumulated inside
the cell. Ultimately, the concentration on both sides of the plasmamem-
brane reach equilibrium and cellular internalization of the drug will
stop.
Endocytosis is a process of internalizing a material that is present
outside the cell (i.e. extra-cellular material) through the invagination
of the plasmamembrane. Endocytosis is an active process ofmass trans-
fer that requires energy expenses from the cell. The following types of
endocytosis are generally identiﬁed: pinocytosis (“cell drinking”)—the
engulﬁng and digestion of dissolved substances; phagocytosis (“cell
eating”)—the engulﬁng and digestion of microscopically visible solid
particles. In turn, endocytosis can be subdivided in two major mecha-
nisms: [1] passive endocytosis when any macromolecular substance is
taken inside the cell without a speciﬁc interaction between the internal-
ized substance and plasma membrane molecules and [2] receptor-
mediated endocytosis when internalization of a molecule or system is
initiated by the speciﬁc interaction between an extracellular receptor
and a targeting ligand speciﬁc to this receptor.
From the point of view of drug delivery and overcoming pump resis-
tance, it is important to understand that endocytized molecules are in-
ternalized in membrane-limited organelles and are inaccessible to the
drug efﬂux pumps. In most cases the drug is released in the deep cyto-
plasm far away from the pumps. Consequently, drugs that enter cancer
cells by endocytosis overcome pump resistance.
3.2.2. Receptor-mediated endocytosis
Interaction of a targeting ligand with its receptor substantially
changes the process of endocytosis of anticancer drugs bound to the li-
gand [89–91]. The main steps of this process are shown very simplisti-
cally in Fig. 5 [92]. Interaction of a ligand bound to the therapeutic
payload with its extracellular plasma membrane receptor leads to the
formation of protein coated pits. These structures represent small
areas of the plasma membrane invaginated into the cell cytoplasm.
They are pinched off the plasma membrane and form protein coated
vesicles. Later, these coated vesicles lose coated proteins and fuse with
endosomes. Decreasing pH and a change in enzymatic environment
inside the endosome lead to the partial dissociation of ligands from
the ligand–receptor complexes. During the process of maturation ofearly endosomes into late endosomes, a change in intravesicular pH
and penetration of enzymes from the Golgi apparatus leads to dissocia-
tion of ligand–receptor complexes and transporting receptors back to
the surface of the cell. Therapeutic payload may also be unbound from
the ligand or ligand containing carrier and be released from early or
late stage endosomes. Late endosomes eventually interact with lyso-
somes by “kissing” via a small contact zone or complete fusion. As a re-
sult, intravesicular pH further decreases and lysosomal enzymes are
able to attack the drug complexes. If the linker between the carrier
and a drug is designed to break under low pH and/or the action of lyso-
somal enzymes (biodegradable linker), the drug is released into the
cytoplasm.
The main advantages of receptor-mediated endocytosis over diffu-
sion and “simple” endocytosis in terms of overcoming cellular drug re-
sistance include the following. First, targeting plasma membrane
receptors not only speeds up the process of endocytosis but also
opens a door for speciﬁc targeting of drug delivery systems to cancer
cells. This is possible if targeted receptors are overexpressed predomi-
nately in cancer cells and their expression in normal non-cancerous
cells is substantially low. Second, similar to “simple” endocytosis, cross-
ing the plasma membrane of cancer cells in coated pit and endosomes
overcomes drug efﬂux pumps. Third, the trafﬁcking in the cytoplasm in-
side membrane-coated organelles protects the encapsulated drug from
the damaging intracellular environment. This phenomenon can also be
used for overcoming nonpump resistance. Fourth, the link between the
active components can be designed in theway that it will disrupt under
the action of low pH and/or lysosomal enzymes. This in turn will
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the cytoplasm. Fifth, lysosomes usually accumulate near the cellular nu-
cleus [93]. It should be stressed that the site of the action of many anti-
cancer drugs is the nucleus. Consequently, the release of the drugs
near their site of action also allows to avoid mechanisms of nonpump
resistance.3.2.3. Active targeting
Targeted drug delivery in cancer chemotherapy usually means that
an anticancer drug or other active component (e.g. siRNA or antisense
oligonucleotides) will be delivered speciﬁcally to the tumor environ-
ment, cancer cells, or speciﬁc organelles inside cancer cells [34].
Targeted drug delivery offers several distinct advantages over non-
targeted delivery of therapeutics. First, it will expose only the tumor
or spread cancer cells to the action of the highly toxic anticancer drug
(Fig. 6). The use of a tumor or cancer cell targeting moiety will enforce
accumulation of chemotherapeutic agents speciﬁcally in the tumor
site leaving healthy organs intact. Active targeting of drugs to the site
of action is important for all kinds of therapy. However, it becomes vital-
ly important in case of chemotherapy when highly toxic anticancer
drugs with potentially strong side effects are used. Cancer targeting
will also initiate the internalization of an entire drug formulation into
cancer cells by receptor mediated endocytosis. This in turn will over-
come existing pump resistance and prevent the development of de
novo resistance. Moreover, after endocytosis, intracellular trafﬁcking in
membrane limited organelles will protect the delivered active compo-
nents against cellular detoxiﬁcationmechanisms and prevent drug deg-
radation, overcoming in this way some or all mechanisms of nonpump
cellular resistance.
Many targeting agents can be used for directing of chemotherapeu-
tic agents speciﬁcally to the tumor site and/or cancer cells. Antibodies or
their fragments, peptides, lectins, sugars and many other types of
targeting moieties can be used [34,84,94–100]. We have proposed
using a luteinizing hormone-releasing hormone (LHRH) peptide to
target different types of drug carriers speciﬁcally to cancer cells
[14,27,28,30–33,73,99,101–106]. Data showed that LHRH receptors
are overexpressed in the plasma membrane of many types of cancer
cells. For instance, Fig. 7A visualizes LHRH receptors in ascitic cells ob-
tained froma patientwith advanced ovarian carcinoma. LHRH receptors
are also expressed in female reproductive organs and the pituitary
gland. However, we found that this expression is signiﬁcantly less pro-
nounced in tumors when compared with healthy tissues of reproduc-
tive organs [33]. Moreover, treating of experimental animals with anConventional Chemotherapy + siRNA 
Drug + siRNA Dru
Tum
Severe Adverse Side Effects
Tumor
Fig. 6. Conventional versus tumanticancer drug targeted by LHRH receptors did not inﬂuence the func-
tion of the pituitary gland [28]. Targeting drug formulations to these re-
ceptors signiﬁcantly enhanced antitumor activity of both anticancer
drugs and siRNA, and prevented severe adverse side effects of chemo-
therapy on healthy organs.
Fig. 4B illustrates the comparison between a passive targeting by the
EPR effect and active targeting of a similar drug formulation by the
LHRH peptide [28]. The distribution of the polymer in mice with and
without tumor was substantially different even when a non-targeted
polymer was used. Moreover, a substantial fraction of radiolabeled rel-
atively high molecular weight non-targeted polymer was accumulated
in the tumor because of the EPR effect. However, a signiﬁcant amount
of non-targeted polymer is still accumulated in other non-cancerous or-
gans. In contrast, the LHRH-targeted polymer preferentially accumulat-
ed in the tumor and a detectable amount of polymer was found only in
the healthy ovary where LHRH receptors are expressed [28,102,105].
Consequently, the measurements of apoptosis induction and histologi-
cal analysis revealed only minimal side effects of cancer targeted che-
motherapy on healthy organs.4. Suppression of drug resistance
4.1. Suppression of pump resistance
4.1.1. Small molecules and antibodies
Many small molecules were proposed to suppress the action of
drug efﬂux pumps. The following classes of drugs were used for this
purpose: calcium channel blockers (verapamil, tiapamil, nifedipine,
prenylamine), quinolines (chloroquine, quinine, quinidine), plant alka-
loids (vindoline), steroids (progesterone), antiestrogens (tamoxifen),
surfactants (Tween-80, cremophor-EL), cyclosporins (cyclosporin A,
PSC-833) and other substances [107–113]. In addition, several marine
natural products with reversal effect on multidrug resistance in cancer,
including agosterol A, ecteinascidin 743, sipholane triterpenoids,
bryostatin 1, and welwitindolinones were tested as inhibitors of pump
resistance [114]. Although, these drugs to a certain extent suppressed
drug efﬂux pumps, in most cases their action was nonspeciﬁc. Conse-
quently, these drugs induced many severe adverse side effects
[115,116]. In addition, the results obtained for many small molecules
as suppressors of pump resistance are biased [117–119]. Consequently,
more speciﬁc inhibitors of drug efﬂux pumps are needed.
Antibodies and their fragments can potentially be used for the sup-
pression of drug efﬂux pumps. However, this approach is more naturalTumor-Targeted Chemotherapy +siRNA
g + siRNA+
or-Targeting
Moiety
Tumor
Limited Adverse Side Effects
or targeted chemotherapy.
A Expression of LHRH protein
Light CD44 Nuclei CD44 + Nuclei
Light LHRH Nuclei LHRH + Nuclei
B Expression of CD44 protein
Fig. 7. Expression of different targeted proteins (immunocytochemistry) in human cancer cells isolated from malignant ascites from patients with advanced ovarian carcinoma. (A) Ex-
pression of LHRH protein. (B) Expression of CD44 protein in cancer stem cells. Representative light and ﬂuorescence microscope images. Proteins were stained using primary antibody
and secondary antibody conjugated with Cy3® ﬂuorofore (red color). Nuclei were stained with DAPI nuclear dye (blue color).
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ticancer drugs. In addition, several limitations and adverse side effects of
antibodies as exogenous immunoactive proteins limit their use for the
suppression of pump resistance.
Many researchers have turned their attention to utilizing natural
products for modulating multidrug resistance by suppressing drug ef-
ﬂux pumps [120]. This direction in the suppression of pump resistance
was especially inspired after disappointing results obtained using the
mentioned above inhibitors. An ideal natural product candidate should
possess a high selectivity and efﬁciency in the suppression of a particu-
lar drug efﬂux pump and simultaneously be relatively non-toxic in
order to minimize the adverse side effects of the treatment. However,
discovery and testing of such compounds is only in the initial stages.
4.1.2. Nucleic acids
Because active drug efﬂux pumps consist of proteins, it is reason-
able to use speciﬁc inhibitors of the expression of these proteins in
order to prevent their normal function. In addition to antibodies,
the most radical inhibitors of protein expression are siRNA and anti-
sense oligonucleotides (ASO). Several effective sequences of siRNA
as ASO targeted to major drug efﬂux transporters were developed
and successfully used in order to inhibit the expression of main
drug efﬂux transporters [16,29,33,73,116,121]. For instance, data ob-
tained in our laboratory show that the suppression of at least one
major drug efﬂux pump by siRNA or ASO can substantially enhance
the anticancer activity of several anticancer drugs in different multidrug
resistant cancer cells [16,18,29,33,73,121]. In addition to traditional
transporters (e.g.P-glycoprotein,MRP, LRP, BCRPproteins), CD44protein
recently attracted the attention both as a marker for cancer stem cells
and as a potential inducer of drug efﬂux transporters. It was found that
this protein co-expresses with P-glycoprotein in the plasma membrane
of cancer stem or cancer initiating cells and its expression correlates
with drug resistance of cancer cells [14,122,123]. Fig. 7B shows that
some cancer cells isolated frommalignant ascites from a patientwith ad-
vanced ovarian cancer overexpress CD44 protein in their plasma mem-
brane. Recently, we found that the suppression of this protein by siRNA
delivered with cancer-targeted nanocarriers decreased the invasiveness
of ovarian cancer cells and increased their drug sensitivity [14].
It should be stressed that the superior speciﬁcity of siRNA that deter-
mines its exceptionally high efﬁciency in the suppression of targeted
mRNA also has its disadvantages. In contrast to anticancer drugsthat can induce cell death in many cancer cells, siRNA with a certain se-
quence can inhibit only one particular protein.Moreover, it might be in-
effective in mutated proteins. Consequently, if several proteins are
responsible for pump drug resistance in certain cancer cells, a mixture
of siRNAs should be used in order to effectively suppress pump resis-
tance and sensitize the cells. On the other hand, it is not practical and
economically not rational to use the same combination of different
siRNAs to treat many types of cancer. It seems that individual selection
of siRNA is required in order to suppress only those drug efﬂux pumps
that are overexpressed in the tumor cells in a particular patient. This ap-
proach requires a personalized selection of the speciﬁc siRNAs in order
to effectively suppress pump resistance in the tumor cells of an individ-
ual patient.
4.2. Suppression of nonpump resistance
4.2.1. Small molecules and peptides
Similar to the suppression of pump resistance, many synthetic or
natural drugs were recently proposed and tested for the suppression
of nonpump resistance of cancer cells. Many proteins responsible for
the nonpump resistance in cancer cells were used as targets. A high di-
versity of mechanisms involved in the development of nonpump resis-
tance determines a wide spectrum of drugs used for sensitizing of drug
resistant cancer cells. The limited scope of this review does not allow
mentioning all drugs used for this purpose. Therefore, we will only
limit the discussion only to the most recently tested drugs.
Some naturally occurring components were used for this purpose.
For example, honokiol, an active compound of Magnolia ofﬁcinalis, ex-
tracts of Spica prunellae (EESP) and Chrysanthemum indicum L., phyto-
alexin brassinin, andrographolide, a diterpenoid lactone isolated from
an herbal plant Andrographis paniculata, emodin, withaferin A and
many others were showed a pro-apoptotic action inmultidrug resistant
cancer cells [124–130]. It is interesting that propofol, one of the most
commonly used intravenous anaesthetic agents during cancer resection
surgery, was found to have cancer sensitizing properties probably asso-
ciated with the suppression of nonpump resistance [131]. Recently, PI3
Kinase/mTOR or HSP90 inhibitors, phosphatidylinositol 3-kinase (PI3K)
inhibitor LY294002 and other drugs were tested as suppressors of
nonpump resistance in cancer cells [132,133]. In addition to lowmolec-
ular drugs, some peptides including antimicrobials, BH3 and other pep-
tides were tested as antiapoptotic drugs [27,28,30,101–104,134,135].
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Antisense oligonucleotides and small interfering RNA can be used
for suppression of proteins mainly responsible for nonpump resistance.
In contrast, transfection of resistant cancer cells with some other
proteins/RNA/DNA can promote apoptosis and suppress nonpump re-
sistance to chemotherapy. The ﬁrst approach (suppression of proteins)
is more widely spread when compared with the second method
(activation of proteins). Huge amount of data about both methods
have been recently accumulated in the literature. Belowwe are present-
ing some examples of the suppression of nonpump resistance bymeans
of nucleic acids.
The major protein that plays an important role in the development
of nonpump resistance is the antiapoptotic BCL2 protein. We have
proposed to inhibit BCL2 protein in order to suppress nonpump resis-
tance and enhance the efﬁcacy of chemotherapy in resistant cancer
cells [16–18,29,31–33,73,106,121,136,137]. Other antiapoptotic and
proapoptotic proteins have been also used as targets for sensitizing re-
sistant cancer cells.
It was found that the overexpression of granulocyte–macrophage
colony-stimulating factor (GM-CSF) protects cells from apoptosis-
stimulating injury through effects on mitochondrial integrity [138].
Moreover, it was found that this protective effect can be eliminated by
treating the cells with GM-CSF-speciﬁc siRNA. Several other siRNAs
targeted to cellular apoptosis susceptibility (CSE1L), immunoglobulin
heavy constant gamma 1 (IGHG1), peroxiredoxins (especially PRDX3),
myeloid cell leukemia-1 (Mcl-1), lung cancermetastasis-related protein
1 (LCMR1), Raf-1, and heat shock proteins (HSP) were tested as a sup-
pressors of nonpump resistance [139–147].
In addition to siRNA targeted to a speciﬁc mRNA, some microRNAs
(miRNAs), small, noncoding RNAs, can be used for the suppression of
nonpump resistance. For instance, it was demonstrated that miR-125b
inhibits BCL2, signiﬁcantly suppresses cancer cell proliferation and in-
duces apoptosis [148].
A different strategy based on the increase in the expression of certain
genes and proteins can potentially be used to sensitize resistant cancer
cells to chemotherapy. For instance, it was found that expression of
miR-195 was low in multidrug resistant breast cancer cells and tissues
[144]. Moreover, overexpression of miR-195 restored the sensitivity of
breast cancer cells to doxorubicin.
Once more, it should be stressed that not all of the mentioned types
of siRNA are effective in all cancer cells. Each type of siRNA effectively
suppresses nonpump resistance only in a limited number of cancer
cells indicating that there is a high diversity of mechanisms of such re-
sistance. Consequently, a high speciﬁcity of siRNA requires an individual
selection of nucleotide type in order to be effectively used for the sup-
pression of nonpump resistance of tumor cells in a particular patient.
5. Targeted proapoptotic drug delivery systems (TPADDS)
We are proposing the concept of a targeted proapoptotic anticancer
drug delivery system that can effectively suppress both pump and
nonpump drug resistance and induce cell death speciﬁcally in cancer
cells. Such system is capable of effectively killing cancer cells and induc-
ing low adverse side effects in normal non-cancerous cells.
5.1. Deﬁnition of TPADDS
First of all, TPADDS is a drug delivery system (DDS). In the broad
meaning of theword, this system is used for the delivery of different ac-
tive components including anticancer drug(s), nucleic acids, peptides,
etc. It actually does not matter what exact type of anticancer agent is
delivered; here we call them all by a generic word “drug”. Such a
“drug” should substantially change a well-being of cancer cells when
delivered inside them. Speciﬁcally, anticancer drugs should induce cell
death, while suppressors of cellular resistance should inhibit pump or/
and nonpump cellular resistance. An entire DDS should effectively killcancer cells by the simultaneous induction of apoptosis and suppression
of mechanisms of cellular drug resistance. Consequently, we have pro-
posed to call such a system as “proapoptotic anticancer” in order to em-
phasize their anticancer action via the effective apoptosis induction
[102]. By deﬁnition, such a system should be very toxic and therefore
can potentially represent a threat for normal non-cancerous cells. To
minimize such adverse side effects on healthy organs and simulta-
neously enhance the internalization of active components by cancer
cells, we proposed to add a targetingmoiety to deliver the entire system
speciﬁcally to the tumor. Many types of targeting moieties can be used
to direct a DDS speciﬁcally to cancer cells [34,84].5.2. Architectures of TPADDS
Based on the type of carrier and architecture of DDS, the systems can
be classiﬁed as follows (Fig. 8) [92]. A simplest type of architecture is
linear DDS that contains no carrier at all or a linear carrier (usually
polymer) with active ingredients conjugated to each other or free sites
of carrier. The carrier may have only two or more conjugation sites.
The number of active components conjugated to a linear carrier can be
substantially increased by employing the branched spacers (schema 4
in Fig. 8A) [30].
A separate type of TPADS architecture is cationic complexes that can
be used for delivering of negatively charged drugs and especially nucleic
acids (Fig. 8B). Any type of carrier that bears a positive charge can po-
tentially be used for this purpose. Such a carrier forms electrostatic com-
plexes with negatively charged nucleic acids mainly resulting in the
formation of nanoparticles of different architecture. Under certain con-
ditions, compact spherical nanoparticles can be formed and successfully
used for effective intracellular delivery of nucleic acids. A substantial
disadvantage of positively charged nanoparticles is their cyto- and
genotoxicity which correlate with their positive charge [149]. While it
looks like cytotoxicity of nanocarriers in chemotherapeutic applications
represents an advantage, in our opinion, it is better to fabricate nontoxic
carriers and use a separate components of DDS that are responsible for
high toxicity of the entire DDS. In this case, only internalization of an en-
tire TPADDS will effectively kill resistant cancer cells. Targeting of DDS
speciﬁcally to the tumor guaranties a low toxicity of TPADDS for normal
non-cancerous cells. If DDS gets destroyed and a carrier enters the sys-
temic circulation, the non-toxic carrier will not represent a substantial
threat for non-cancerous normal cells. Recently, we proposed several
methods of modifying cationic carriers in order to decrease their cyto-
and especially genotoxicity with preserving their high ability to form
complexes with nucleic acids and deliver them inside cancer cells
[31,99,149–152]. One of these modiﬁcations is schematically presented
in Fig. 9 [99,149–151]. The traditional cationic poly(amido amine)
(PAMAM) dendrimer has a positive charge and NH2 residues located
on its surface (Fig. 9A). Such dendrimers demonstrated cytotoxicity
(Fig. 9B), low ability to penetrate cancer cells (Fig. 9C) and genotoxicity
(Fig. 9D). The proposed modiﬁcation includes a surface modiﬁcation
and moving a positive charge from the surface of the dendrimer
(Fig. 9A, right panel). The resulting internally cationic and surface-
modiﬁed dendrimer demonstrated low cytotoxicity (Fig. 9B), high
ability to deliver nucleic acids inside cancer cells (Fig. 9C) and low
genotoxicity (Fig. 9D). Other modiﬁcations were proposed and tested
in our laboratory that enhanced stability and penetration ability of dif-
ferent carriers while decreasing their cyto- and genotoxicity [149].
Complex neutral, positively or negatively charged DDS can be
constructed using nanocarriers of different architectures (Fig. 8C).
These DDS can have liposomes, micelles, dendrimers or other nanopar-
ticles as carriers and contain active components on the surface of a car-
rier and/or inside a nanoparticle. These components may be conjugated
via spacers or physically trapped inside porous nanoparticles. For more
detailed description of TPADDS architecture and other properties the
reader is referred to our recent book chapter [92].
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Fig. 8. Examples of the most common architectures of drug delivery systems. Modiﬁed from [92].
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We are proposing to develop and validate an innovative approach of
personalized treatment of different cancers based on the individual ge-
netic proﬁle of the patient's tumor. The following treatment protocol
may be proposed for a personalized selection of treatment mode for dif-
ferent individuals. Samples of the patient's tumor and normal surround-
ing tissues are obtained and predeﬁned gene/protein expression proﬁles
are analyzed (Fig. 10). Based upon results of this analysis, several molec-
ular targets and themost effective anticancer drug(s) are selected. Final-
ly, the patient is treated with the mixture of selected TPADDS. The
systems will include tumor-targeted polymeric complex containing the
most effective drug or siRNA selected for each individual patient based
on a genetic proﬁle of the patient's tumor (Fig. 10). It is expected that
such personalized therapy will effectively suppress drug resistance and
enhance tumor cell death in the particular patient. Consequently, the
main goal of the proposed approach is to identify a gene/protein expres-
sion and single-nucleotide polymorphism proﬁles that correlate with re-
sistance of tumor cells obtained fromeach individual andwith efﬁcacy of
chemotherapy for the same patient. The approach also includes the de-
velopment of a set of TPADDS containing anticancer drug(s) or siRNA(s)
targeted to different mRNAs overexpressed in the proﬁle of the patient.
Although, the proposed personalized treatmentmethodology is only
at an initial stage of its development and require further extensive and
detailed investigation, several experimental lines of evidence can be
provided to support a feasibility of this approach. These data are sum-
marized below.
6.1. Correlation between cellular resistance to doxorubicin and mutations
in topoisomerase II alpha
Ovarian cancer cells were isolated from samples of primary and
metastatic tumors obtained from patients with ovarian carcinoma.
Cytotoxicity of doxorubicin (DOX) and camptothecin (CPT) wasdetermined for each sample. It was found that the IC50 dose for
DOX varied over a very broad range of 3 to 130 μM. In contrast, the
variation in cytotoxicity for CPT was substantially less pronounced
(IC50 varied from 60 to140 nM). The histogram of the distribution
of IC50 values for DOX (Fig. 11A, black curve) demonstrated a clear
subdivision of samples on two groups with ranges of 3–12 and
50–150 μM. The latter group could potentially be subdivided into 2
or 3 subgroups (the sample size in this group was too small to
make a decision based solely on the histogram).
It is generally considered that the main mechanism of DOX toxicity
involves an interaction with DNA by intercalation and inhibition of
macromolecular biosynthesis [153,154]. Doxorubicin stabilizes the
topoisomerase II alpha (TOP2A) complex after it has broken the DNA
chain for replication, preventing the DNA double helix from being
resealed and thereby stopping the process of replication. Consequently,
mutations in TOP2A might inﬂuence the DOX cytotoxicity. Hinds et al.
[155] found that resistance of some cancer cells to inhibition of topo-
isomerase II alpha by amsacrine and other intercalating agents was
due to a single base change: AGA (arginine) to AAA (lysine). The single
base change was at nucleotide 1493 of the TOP2A gene, resulting in a
change in amino acid 486. Analysis of this mutation in our samples
by SNPWare96 kit (Orchid BioSciences, Princeton, NJ) showed that
the majority of tumor samples have a wild GG genotype, while some
samples have heterozygote AG (N= 4) and homozygote AA (N= 5)
genotypes (Fig. 11B). It was further found that cells with a mutation
in TOP2A gene have signiﬁcantly greater resistance to DOX (Fig. 11C).
It is interesting that cells with both AG and AA TOP2A genotype did
not show statistically signiﬁcant differences in cytotoxicity to CPT
(126.2 ± 8.1 and 131.1 ± 9.6 nM, respectively) when compared with
cells with the wild genotype (GG). When normal distributions of all
three groups (GG, AG, and AA) were calculated based on experimental
values of means, standard deviation and size of each group plotted over
an experimental histogram (Fig. 11A, green, red and blue curves), a sat-
isfactory agreement (for the sample size) was demonstrated. These
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plained by the TOP2A mutations. However, the mutation alone cannot
explain individual variations of resistance to DOX within each group,
because samples for each group were selected based on the same
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defense (nonpump resistance) [15–18,135]. In order to obtain prelimi-
nary data supporting this premise, we measured the expression of
MDR1 and BCL2 mRNA, encoding P-glycoprotein and BCL2 protein, the150
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The correlation between DOX IC50 values and expression of MDR1 and
BCL2 was analyzed for all experimental groups (Fig. 12). It was found
that the resistance of cells inside each group correlated positively with150
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1892 T. Minko et al. / Advanced Drug Delivery Reviews 65 (2013) 1880–1895the expression of MDR1 mRNA with the exception of a small number of
the most resistant cells in group GG that have IC50 values higher than
8 μM (indicated with black circles on Fig. 12A). A slight, but statistically
signiﬁcant, positive correlation was found only in cells from the GG
group, which has an IC50 valueN5μM. Therefore, in most cases the resis-
tance of cancer cellswithin a corresponding genotyping group correlated
with the expression of MDR1 mRNA. A substantially weaker correlation
between resistance to DOX and BCL2 expression was found only in the
group with high level of resistance and wild TOP2A genotype (GG).
In order to provide additional preliminary data related to themecha-
nisms responsible for differences in IC50 levels in cells with thewild type
of TOP2A gene, we conducted a microarray measurement of the expres-
sion of several thousand genes (32 column by 144 row slide format) in
two samples from this group having distinctly different DOX IC50 values
of 4.89 and 11.17μM, respectively. Fifteen genes were identiﬁed as hav-
ing a different expression in these samples (Fig. 13). Although these dataA Gene Expression 
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Animals treated with LHRH-PEG-DOX-MRP1 siRNA TPADDS; 4—Animals treated with LHRH-Pare too preliminary to make conclusions, they demonstrate that some
genes have different expressions in samples possessing different resis-
tance to DOX. Previously, we showed that the overexpression of at
least three of these genes (CFOS, HSP70 and HCP90) is responsible in
part for the resistance of ovarian cancer cells to the treatment with
DOX [35,36,145,147].
In order to further support the proposed personalized approach to
cancer treatment, we selected cells isolated from tumor samples of two
patients with ovarian cancer and used them to initiate subcutaneous
tumor in nude mice. In both cases, we observed high resistance to treat-
ment with DOX. However, in the ﬁrst case, cells overexpressed theMRP1
gene and therefore their resistance was attributed to the overexpression
ofmultidrug resistance-associated protein 1. The resistance of the second
tumor was mainly attributed to the overexpression of CD44 protein.
Consequently, animals were divided in two groups based on the genes
overexpressed in their tumors—MRP1 or CD44 (Fig. 14A and C). AllB
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1893T. Minko et al. / Advanced Drug Delivery Reviews 65 (2013) 1880–1895animals were treated with saline (control), free DOX and targeted
TPADDS containing LHRH as a tumor targeting moiety, PEG polymer as
a carrier, DOX as an anticancer drug and siRNA targeted to MRP1 or
CD44 mRNA. It was found that the delivery system containing siRNA
targeted to MRP1 mRNA (LHRH-PEG-DOX-MRP1 siRNA TPADDS) was
themost effective in theMRP1 expression groupwhile the complex con-
taining siRNA targeted to CD44 mRNA (LHRH-PEG-DOX-CD44 siRNA
TPADDS) was primarily efﬁcient in the CD44 expressing group. There-
fore, these preliminary data support our concept of the selection of
TPADDS based on the gene/protein expression proﬁle in the tissues ob-
tained from the tumor of each individual patient.
7. Future directions
We hope that the ideas presented in this manuscript would attract
the attention of both basic and clinical researchers to the individualized
tactic to suppression ofmultidrug resistance and in broader terms to the
challenges of personalized cancer treatment. In contrast to other
methods that require a huge amount of data collected on a wide popu-
lation of patients with different cancers and require a gigantic amount
of bioinformatics support, our approach is based on a pretty simple
and straightforward concept. Samples of normal (non-tumorous) and
tumorous tissues are obtained and the expression of genes responsible
for multidrug resistance is analyzed in tumor cells versus normal cells
obtained from the same individual. Such analysis can be done in an au-
tomatedway using the predeﬁned already available kits or a speciﬁcally
designed set of primers. Mutations of certain genes (if their role in the
development of resistance to chemotherapeutic drugs is conﬁrmed)
can also be involved in the analysis on the later stage of the develop-
ment of the approach. In parallel, cells are isolated from the patient's
tumor andwill be grown in cell culture conditions. Based on the individ-
ual expression proﬁle of the patient's tumor, one or most probably sev-
eral TPADDS are selected from a bank of available drugs. The efﬁciency
of the selected anticancer drug(s) and siRNA targeted to overexpressed
protein mRNAs is conﬁrmed using the isolated cells. In certain situa-
tions, efﬁciency of the selected mixture of TPADDS can be conﬁrmed
on a xenograft tumor model created using the same isolated tumor
cells. After such conﬁrmations, the mixture of the selected TPADDS is
applied to the patient. Even a small set of our preliminary data, as well
as analysis of publications of other researchers, give us a conﬁdence in
the proposed approach. We hope that this publication triggers interest
and criticism from a wide audience. If this happens, we will consider
the major aim of this publication as achieved.
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